Western Digital Corp
Change company Symbol lookup
Select an option...
WDC Western Digital Corp
QYLD Global X NASDAQ 100 Covered Call ETF
SPHD Invesco S&P 500® High Dividend Low Volatility ETF
WMT WALMART STORES INC
BROG Brooge Holdings Ltd
EMRAF Emera Inc
PPL PPL Corp
PG Procter & Gamble Co
CLOU Global X Cloud Computing ETF Global X Cloud Computing ETF
GDRX Goodrx Holdings Inc
Go

Information Technology : Technology Hardware, Storage & Peripherals | Mid Cap Value
Company profile

Western Digital Corporation (Western Digital) is a developer, manufacturer and provider of data storage devices and solutions that address the needs of the information technology (IT) industry and the infrastructure that enables the proliferation of data in virtually every industry. The Company's portfolio of offerings addresses three categories: Datacenter Devices and Solutions (capacity and performance enterprise hard disk drives (HDDs), enterprise solid state drives (SSDs), datacenter software and system solutions); Client Devices (mobile, desktop, gaming and digital video hard drives, client SSDs, embedded products and wafers), and Client Solutions (removable products, hard drive content solutions and flash content solutions). The Company develops and manufactures a portion of the recording heads and magnetic media used in its hard drive products.

Postmarket

Last Trade
Delayed
$44.90
0.02 (0.04%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$44.88
Day's Change
-0.97 (-2.12%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
46.54
Day's Low
44.74
Volume
(Heavy Day)
Volume:
4,834,076

10-day average volume:
3,896,748
4,834,076

Global Pneumonia Therapeutics Market Trajectory & Analytics Report 2020 Featuring Abbott Labs, Allergan, Bayer, GlaxoSmithKline, Lupin Pharma, Merck & Co, Novartis & Pfizer - ResearchAndMarkets.com

7:28 am ET October 2, 2020 (BusinessWire) Print

The "Pneumonia Therapeutics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Global Pneumonia Therapeutics Market to Reach US$22.5 Billion by the Year 2027

Amid the COVID-19 crisis, the global market for Pneumonia Therapeutics estimated at US$14.5 Billion in the year 2020, is projected to reach a revised size of US$22.5 Billion by 2027, growing at a CAGR of 6.5% over the analysis period 2020-2027.

Drugs, one of the segments analyzed in the report, is projected to grow at a 2.7% CAGR to reach US$5.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Vaccines segment is readjusted to a revised 8.3% CAGR for the next 7-year period. This segment currently accounts for a 63.1% share of the global Pneumonia Therapeutics market.

The U. S. Accounts for Over 29.5% of Global Market Size in 2020, While China is Forecast to Grow at a 6.2% CAGR for the Period of 2020-2027

The Pneumonia Therapeutics market in the U. S. is estimated at US$4.3 Billion in the year 2020. The country currently accounts for a 29.45% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$4 Billion in the year 2027 trailing a CAGR of 6.2% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.6% and 5.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.7% CAGR while Rest of European market (as defined in the study) will reach US$4 Billion by the year 2027.

Oxygen Therapy Segment Corners a 4.7% Share in 2020

In the global Oxygen Therapy segment, USA, Canada, Japan, China and Europe will drive the 4.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$544.8 Million in the year 2020 will reach a projected size of US$733 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$2.6 Billion by the year 2027.

The report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others:

Abbott Laboratories Allergan PLC Bayer AG GlaxoSmithKline PLC Lupin Pharmaceuticals, Inc. Merck & Co., Inc. Novartis AG Pfizer, Inc.

Key Topics Covered:

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Impact of Covid-19 and a Looming Global Recession Global Competitor Market Shares Pneumonia Therapeutics Competitor Market Share Scenario Worldwide (in %): 2018E

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

World Current & Future Analysis for Pneumonia Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2018 through 2027 World Historic Review for Pneumonia Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 World 15-Year Perspective for Pneumonia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2018 & 2027 World Current & Future Analysis for Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2018 through 2027 World Historic Review for Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 World 15-Year Perspective for Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027 World Current & Future Analysis for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2018 through 2027 World Historic Review for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 World 15-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027 World Current & Future Analysis for Oxygen Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2018 through 2027 World Historic Review for Oxygen Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 World 15-Year Perspective for Oxygen Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

IV. COMPETITION

Total Companies Profiled: 68

For more information about this report visit https://www.researchandmarkets.com/r/mz1zhw

View source version on businesswire.com: https://www.businesswire.com/news/home/20201002005240/en/

SOURCE: Research and Markets

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com 
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.